secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHAMPIONS ONCOLOGY, INC. (CSBR)
CIK:        0000771856
Form:       8-K
Filed at:   2023-09-13T23:59:59+00:00
Accession:  0001628280-23-032185
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Champions Oncology Q1 revenue $12.6M, down 9%; operating loss widens to $2.6M
-----------------------------------------------------------------------------

- Revenue $12.6M vs $13.7M YoY (-8.6%); gross margin 38.8% vs 48.7%.
- Operating loss $2.6M vs loss of $284K; adjusted EBITDA loss $1.7M vs positive $450K.
- Cash $5.0M, no debt; net cash used in ops $4.0M for the quarter.
- CEO cites biotech downturn; bookings improving, expects revenue growth in H2.
- Drug discovery subsidiary Corellia AI progressing; company seeking capital to accelerate programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/771856/000162828023032185/0001628280-23-032185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/771856/000162828023032185/csbr-20230913.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-032185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer